Key Takeaways on the Management of Atopic Dermatitis

EP: 1.Atopic Dermatitis Overview: Pathophysiology, Diagnosis, and Burden

EP: 2.Treatment for Mild to Moderate vs Moderate to Severe Atopic Dermatitis

EP: 3.JAK Inhibitors in Atopic Dermatitis: Historical Use and Mechanisms of Action

EP: 4.Topical Ruxolitinib Use in Atopic Dermatitis

EP: 5.Recent Approval of Oral JAK Inhibitors for Atopic Dermatitis

EP: 6.Atopic Dermatitis: Practical Advice on Selecting and Using JAK Inhibitors

EP: 7.Ongoing Challenges in the Management of Atopic Dermatitis

Now Viewing

EP: 8.Key Takeaways on the Management of Atopic Dermatitis

Transcript:
Christopher G. Bunick, MD, PhD: Before we end this discussion, I’d like to get some final thoughts from each of our panelists, who’ve done such a wonderful job enlightening all of us about atopic dermatitis and JAK inhibitors. Dr Cohen, let’s start with you. Some final thoughts.

Jeffrey Cohen, MD: It’s an exciting time to be a dermatologist and to be treating atopic dermatitis. Every day we’re learning more about new therapies. We now have 3 or 4 new treatments that have come out in the past several months, so we now have a lot more options for our patients. It’s made taking care of these people a pleasure because we can talk to them about more new things. We can tell them ways that we may be able to improve their skin condition. At the end of the day, that’s what makes us all happy and makes us all tick: to help patients achieve the best skin disease control they can. With these new medications, it’s an exciting time to try to do that.

Christopher G. Bunick, MD, PhD: Great, thank you. Dr Stein Gold, last thoughts?

Linda F. Stein Gold, MD: Education is key. As dermatologists we owe it to ourselves and our patients to become educated on the new drugs, to make sure you understand the risks and the benefits, to make sure we pick the right patients. [Then we have to] educate our patients that this is a chronic condition. We have to get them under control and keep them under control, and it’s going to be a team effort. We’re going to have to work together, but we do have new tools that are going to make this a very successful process.

Christopher G. Bunick, MD, PhD: Great. Dr Lio, bring us to a close.

Peter A. Lio, MD: Once I was at a meeting and we were in a shuttle bus going from some venue to another, and I heard 2 clinicians in front of me talking about 1 of the new treatments. They were kind of disparaging. They were like, “Why would we need this? We have topical steroids. Where would you use this? Who needs it?” And I thought to myself, “This is such a heterogeneous disease, and there are so many individual needs.” Honestly, I need all the tools I can get, because the patients I often get referred have tried a bunch of the main things. For every new treatment, I always like the phrase “Every pot has a lid.” For each medicine, there’s probably a patient out there who could say, “This is the 1 for me.” Some are better than others, some are not so great, but having this kind of a palette allows us to be able to take care of everybody on an individual level.

Christopher G. Bunick, MD, PhD: That heterogeneity that you speak of is exactly why precision molecular medicine, why innovation in dermatology, has taken off in the last few years: to try to deal with this heterogeneity.

I’d like to thank our 3 panelists 1 more time, and I’d like to thank all of you watching this Dermatology Times® Viewpoints presentation. We hope you found this very educational. Thank you.

Transcript edited for clarity.